Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Paying For Gene Therapy: Medicaid Will Be ‘Canary In Coal Mine’

Executive Summary

Harvard Pilgrim's Michael Sherman and Cigna's Steve Miller advise gene therapy developers to consider the burden of high cost treatments on Medicaid programs when setting list prices.

You may also be interested in...



Calls For National Tech Assessment Program Could Be Amplified By Costs Of Cell, Gene Therapy

Speculation is growing that the Institute for Clinical and Economic Review or something like it could become the US version of the government-sponsored health tecnology assessment bodies in Europe.

Curative Gene Therapy Coverage May Need Government-Funded Risk Pools

Former US FDA commissioner Scott Gottlieb makes a case for regional or national risk pools to ensure pediatric patients get timely access to gene therapy like the upcoming treatments for sickle cell disease.

Employers Would ‘Welcome’ Government Role In Covering High-Cost Therapies

Annual large employer health benefits survey for 2020 and beyond finds support for government price negotiation and payment through a national fund. Plans to expand point-of-sale rebates and coupon accumulator programs also reported.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS125210

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel